Management of Beta Blocker Overdose
Introduction
- Beta blocker overdose requires prompt and effective treatment to prevent severe toxicity and improve outcomes, as recommended by the American Heart Association 1, 2, 3, 4
First-Line Treatment
- High-dose insulin therapy with glucose supplementation is recommended as the first-line treatment for beta blocker overdose refractory to or in conjunction with vasopressor therapy, with a Class 1, B-NR recommendation indicating the highest level of recommendation with moderate-quality evidence, and is associated with favorable outcomes and lower rates of vasoconstrictive complications compared to vasopressor-only therapy, as stated by the American Heart Association 1, 2, 3
- High-dose insulin euglycemic therapy is recommended with an initial bolus of 1 U/kg IV, continuous infusion of 1 U/kg/hour, and titration based on clinical response, co-administered with dextrose, with a Class 1, B-NR evidence rating 2, 1, 3
Alternative Therapies
- IV glucagon is recommended as first-line or second-line treatment, with a dosing regimen of 5-10 mg IV bolus over 3-5 minutes, followed by a continuous infusion of 1-5 mg/hour, with caution for potential vomiting and airway protection, and a Class 2a, C-LD evidence rating 2, 1, 3
- Vasopressors (e.g., epinephrine, norepinephrine, dopamine) are recommended as first-line treatment, titrating to effect based on blood pressure response, with a Class 1, C-LD evidence rating 1, 3
- Calcium administration may be considered, with calcium chloride or calcium gluconate IV, and may be repeated every 10-20 minutes for 3-4 doses if beneficial, with a Class 2b, C-LD evidence rating 2, 1, 3
- Atropine may be used for symptomatic bradycardia, with a dose of 0.5-1 mg IV, but often has limited efficacy in beta-blocker overdose, with a Class 2b, C-LD evidence rating 2, 1, 3
Special Considerations
- Patients with liver disease are at higher risk for carvedilol toxicity, even at therapeutic doses, and may require lower treatment thresholds and more aggressive management, as recommended by the American Heart Association 1
- Patients on chronic beta blocker therapy should avoid abrupt withdrawal, as it can lead to clinical deterioration, as stated by the American Heart Association 4
- The following patient populations require special consideration:
| Patient Population | Consideration |
|---|---|
| Patients with liver disease | Higher risk for carvedilol toxicity, even at therapeutic doses, and may require lower treatment thresholds and more aggressive management [1] |
| Patients on chronic beta blocker therapy | Abrupt withdrawal can lead to clinical deterioration, as stated by the American Heart Association [4] |
Treatment Monitoring and Adjunctive Therapies
- Continuous cardiac monitoring, blood glucose, potassium, and lactate levels, hemodynamic parameters, neurobehavioral status, and intake and output balance are recommended for monitoring 1, 3
- Gastric decontamination is considered only for recent ingestions with protected airway, although the guideline society is not specified in the provided text 3
- Hemodialysis is not recommended for propranolol toxicity due to high protein binding and lipophilicity, as stated by the Critical Care journal in 2021 3
- Extracorporeal Life Support (VA-ECMO) may be considered for life-threatening poisoning with cardiogenic shock unresponsive to pharmacological interventions, with early consultation with ECMO team recommended, and a Class 2a, C-LD evidence rating 2, 1, 3